Skip to main content

Open-label Trial in Parkinson's Disease (PD)

Completed · Phase 3 · NCT04760769

Conditions: Parkinson Disease

At a glance

Research payments reported, 2025
$538,223
U.S. investigators named
36
Sites paid
34
Planned or actual enrollment
992

About the trial

Sponsor
AbbVie
Tested
Tavapadon (drug)
Dates
Started 2021-02-24; completion 2025-12-01
Results posted
Not yet

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.

From ClinicalTrials.gov, last updated 2025-12-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $538,223 in research payments for this study in 2025 (156 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.